Drug intelligence / Profile preview

TNFAIP3 siRNA

Development stage
Unknown
Lead developer
University of Bern
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intrathecal
01

Overview

TNFAIP3 siRNA is a small interfering RNA designed to silence the expression of the TNFAIP3 (Tumor Necrosis Factor Alpha-Induced Protein 3) gene, which encodes the A20 protein. A20 is a potent zinc-finger protein that serves as a critical negative regulator of the NF-κB signaling pathway, helping to terminate inflammatory responses. In oncology research, particularly concerning gliomas and glioblastomas, TNFAIP3 siRNA is utilized as a tool to investigate the molecular mechanisms of resistance to alkylating agents like temozolomide (TMZ). Knockdown of TNFAIP3 leads to the constitutive activation of NF-κB, which in turn upregulates anti-apoptotic proteins such as Bcl-2 and BIRC3, conferring resistance to TNF-alpha and TRAIL-induced apoptosis. Research indicates that TNFAIP3 is a direct target of microRNAs miR-125a and miR-125b, and siRNA-mediated inhibition of TNFAIP3 mimics the phenotype of miR-125a/b overexpression in promoting tumor cell survival and therapy resistance.

Other names
A20 siRNAA-20 siRNAA 20 siRNATNFAIP3 small interfering RNATNFAIP-3 small interfering RNATNFAIP 3 small interfering RNAsiRNA directed against TNFAIP3
02

Targets

TNFAIP3 (Tumor necrosis factor alpha-induced protein 3)

Beyond the preview

Go deeper on TNFAIP3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNFAIP3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call